Subsea 7 - Confirms award offshore Norway Luxembourg – 19 December 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract for pre-commitment to procure long lead items for a project in the Norwegian North Sea.Pre-execution project management and engineering work will commence immediately at Subsea7’s office in Stavanger, Norway. Erik Femsteinevik, VP Subsea7 Norway, said: “This early commitment to long lead items reflects the strong, trust‑based relationship with the operator and enables early engagement and fast-track development.” 1.Subsea7...
Subsea 7 - awarded contract offshore Norway Luxembourg – 19 December 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 extension of an existing frame agreement by Equinor for subsea inspection, maintenance and repair services (IMR), for vessel Seven Viking. This is the latest extension to the frame agreement, first signed in 2018. Under the terms of the extension, to the end of 2027, Seven Viking will carry out inspection, maintenance and repair (IMR) services for subsea operations at Equinor’s oil and gas wells across the Norwegian Continental She...
Subsea 7 - Awarded contract offshore Norway Luxembourg – 18 December 2025 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a large1 contract by ConocoPhillips Skandinavia AS (ConocoPhillips) for the Previously Produced Fields (PPF) development, offshore Norway. Subsea7’s scope covers engineering, procurement, construction and installation (EPCI) of subsea structures, umbilicals, risers and flowlines (SURF). It follows the award on 19 May 20252 of a contract for front-end engineering and design that finalised the technical definition of the development. Enginee...
Transgene annonce ses prochaines rencontres avec les investisseurs Strasbourg (France), le 17 décembre 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce aujourd'hui que son équipe de direction rencontrera des investisseurs institutionnels lors des prochaines éditions de : LifeSci Partners Corporate Access Event (par LifeSci Partners), les 12 et 13 janvier 2026, à San Francisco (États-Unis) en parallèle de la conférence JP Morgan Healthcare;Biomed Forum (par Alli...
Transgene to Participate in Upcoming Investor Meetings Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of: LifeSci Partners Corporate Access Event (by LifeSci Partners), on January 12 and 13, 2026, in San Francisco (United States) in conjunction with the JP Morgan Healthcare Conference;Biomed Forum (by Allinvest Securities), on January 29, 2026, i...
Subsea 7 - Awarded contract offshore Australia Luxembourg –16 December 2025 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced a substantial1 award by Chevron Australia. The contract covers subsea installation on the Gorgon Stage 3 (GS3) Project, offshore Australia. Subsea7’s scope of work includes project management, engineering, procurement, fabrication, transportation, installation and pre-commissioning of subsea equipment and associated infrastructure at GS3, at 1,350m water depth. Project management and engineering work will commence immediately from Subsea7’s office in Pe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.